Oxford Heartbeat secures ethics and HRA approval to commence clinical trials and test the effectiveness of its CE-marked medical software PreSize® Neurovascular in real-world clinical settings.
PreSize® trial receives ethics and compliance approval

Oxford Heartbeat secures ethics and HRA approval to commence clinical trials and test the effectiveness of its CE-marked medical software PreSize® Neurovascular in real-world clinical settings.
New Innovate UK award will help extend the power of Oxford Heartbeat’s cutting-edge AI software PreSize Neurovascular
Oxford Heartbeat’s software PreSize® Neurovascular is on track to be introduced within the NHS.
Our CEO Katerina shares her insights on how entrepreneurship has enabled her to contribute to medicine.
The award comes directly from the UK government, and funds a trial of PreSize® at 6 NHS hospitals.
Our CEO Katerina, a Royal Academy of Engineering Fellow, speaks about the joys and challenges of entrepreneurship.
Acquiring CE marking for novel medical devices is often a complex process.
PreSize® Neurovascular is now deemed ready for market release at all hospitals across the EU and UK.